2024-12-10 - Analysis Report
## Johnson & Johnson (JNJ) Stock Review

**1) Performance Comparison & Divergence:**

Johnson & Johnson (JNJ), a global healthcare company that manufactures pharmaceuticals, medical devices, and consumer packaged goods, significantly underperformed the S&P 500 (VOO) over the measured period.  While JNJ showed a cumulative return of 27.15%, VOO achieved a 121.38% return.  This represents a substantial divergence, with JNJ lagging behind by -94.5 percentage points.  The provided data shows a maximum divergence of 17.7% and a minimum of -94.5%, with the current divergence at -94.5%.  The relative divergence is 0.0, indicating a complete lack of relative performance compared to the benchmark.

**2) Current Stock Price:**

The closing price of JNJ is $149.31.  The last market price is reported as $149.61.

**4) Recent Earnings Analysis:**

The provided earnings data reveals a mixed picture for JNJ:

* **Latest Quarterly Results Comparison:**  EPS shows significant variability across quarters, ranging from $1.12 to $1.95. Revenue remains relatively stable around the $22B mark, with minor fluctuations.  The exceptionally high EPS of $10.32 in Q4 2023 is an outlier that requires further investigation beyond the provided data (potential accounting adjustments or one-time events).

* **Revenue Growth Trends:** Revenue growth is minimal and inconsistent across the reported quarters, showing no clear upward or downward trend.

* **EPS Trends and Significant Changes:** EPS is highly volatile, demonstrating no consistent trend. The substantial spike in Q4 2023 warrants additional context to understand the underlying drivers.

* **Beats or Misses:**  Without expectations data, it's impossible to determine whether the reported EPS and revenue figures beat or missed analyst expectations.

**5) Financial Information Analysis:**

* **Revenue and Profitability:** Revenue is relatively stable, fluctuating around $22 billion. Profit margins are consistently high, ranging from 68.23% to 69.55%, suggesting strong profitability.

* **Capital and Profitability:** Equity shows some fluctuation, and Return on Equity (ROE) is also inconsistent, ranging from 3.84% to a remarkably high 36.54% in Q3 2023.  This extreme variation in ROE requires further analysis to identify the causes, as it significantly deviates from the other quarterly figures.


**6) News and Recent Issues:**

No specific news or recent earnings announcements within the last two days are provided.  Information on market outlook and analyst opinions is missing.

**7) Overall Analysis:**

JNJ's performance significantly lags the S&P 500, indicating underperformance. While profitability (profit margins) remains consistently high, revenue growth is stagnant, and EPS is highly volatile. The extremely high ROE in Q3 2023 and the unusually high EPS in Q4 2023 are major outliers requiring further investigation to understand the underlying factors.  Without additional data (analyst expectations, industry comparisons, and context for the Q3 2023 ROE and Q4 2023 EPS spikes), a comprehensive evaluation is limited.  The analysis presented here is solely based on the provided data points.  More information is needed for a complete and accurate assessment of JNJâ€™s current financial health and future prospects.


**8) Disclaimer:** This report is based solely on the limited data provided.  It is not financial advice and should not be used as the sole basis for investment decisions.  Consult with a financial professional before making any investment choices.
